Shionogi.com

HOME

ABOUT US

PRODUCTS

RESPONSIBILITY

CAREERS

Company Overview

Company History

Management Team

Our Headquarters

Anti-infectives

Cardiovascular/Diabetes

Pain

Pediatrics

Women's Health

Other

Overview

Compliance Program

Supplier Diversity Program

PO Terms & Conditions

Products — Anti-infectives

Moxatag^© Tablets
www.moxatag.com
Prescribing Information

KEFLEX^©
Prescribing Information

Products — Cardiovascular/Diabetes

Sular with Geomatrix Forumation^© Tablets
www.sular.com
Prescribing Information

Fortamet^© Tablets
www.fortamet.com
Prescribing Information

Triglide^© Tablets
www.triglide.com
Prescribing Information

Altoprev^© Tablets
www.altoprev.com
Prescribing Information

Products — Pain

Naprelan^© Tablets
www.naprelanus.com
Prescribing Information

Dolgic^© Tablets
Prescribing Information

ZEBUTAL^© Capsules
Prescribing Information

XODOL^© Tablets
Prescribing Information

Magnacet^© Tablets
Prescribing Information

Fexmid^© Tablets
Prescribing Information

Naprelan^® is a registered trademark of Elan Corporation, PLC.

Products — Pediatrics

Mythylin^© Chewable Tablets & Methylin^© Oral Solution
www.methlylinrx.com
Prescribing Information Chewable Tablets Prescribing Information Oral Solution

Products — Women's Health

Osphena^™ Tablets
www.osphena.com
Full Prescribing Information
Patient Information

Products — Other

Robinul™ is a registered trademark of Wyeth LLC

PRESS RELEASES

05/07/2013
Shionogi Inc. Divests and exclusively licenses its pediatric products to Concordia Pharmaceuticals Inc.

02/26/2013
Shionogi Receives FDA Approval for OsphenaTM (ospemifene)

Press Releases

05/07/2013
Shionogi Inc. Divests and exclusively licenses its pediatric products to Concordia Pharmaceuticals Inc.
Read More > 02/26/2013
Shionogi Receives FDA Approval for OsphenaTM (ospemifene)
Read More > 01/08/2013
Shionogi & Co., Ltd. files patent infringement action in the U.S. District Court in New Jersey on December 28, 2012, regarding Sandoz’s submission of an Abbreviated New Drug Application with the FDA seeking approval for a generic version of Doribax(r)
Read More >